Treatment of recurrent cervical adenocarcinoma with BMS-247550, an epothilone B analog.
OBJECTIVE
The incidence of recurrent cervical adenocarcinoma is rising relative to the squamous subtype. There are limited therapeutic options for women with advanced cervical adenocarcinoma. Only a few chemotherapy agents have demonstrated activity in this disease. This report describes results with BMS-247550, an epothilone B analog that stabilizes microtubules, with activity in previously treated adenocarcinoma of the cervix.


METHODS
We present two women with recurrent cervical adenocarcinoma with metastases to the lung. Both women were treated previously with paclitaxel and were enrolled in a phase I study with BMS-247550. Both women had partial responses to BMS-247550 with a decrease in tumor size and CA-125 levels.


CONCLUSIONS
The demonstration of a response to BMS-247550, especially after additional chemotherapy had been administered, is encouraging, albeit preliminary. The ultimate role of BMS-247550 and multiagent chemotherapy in the treatment of adenocarcinoma of the cervix should be further investigated.
Agrawal
Manish
M
Center for Cancer Research, National Cancer Institute Building 10/12C103, 9000 Rockville Pike, Bethesda, MD 20892, USA.
Edgerly
Maureen
M
Fojo
Tito
T
Kotz
Herb
H
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000556:secondary; D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D034261:Epothilones / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000556:secondary; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy* / Q000473:pathology
D000970:Antineoplastic Agents; D034261:Epothilones; C430592:ixabepilone